Peripheral blood CD4posCD25posFoxP3pos cells and inflammatory cytokines as biomarkers of response in rheumatoid arthritis patients treated with CTLA4-Ig

Table 1 Demographic and clinical characteristics of RA patients treated with CTLA4-Ig at study entry

	Whole RA cohort (n = 34)	RA cohort 1 (n = 15)	RA cohort 2 (n = 19)	p*
Age, years	56.2 ± 14.8	56.5 ± 15.6	55.8 ± 14.5	0.55
Sex, n, female (%)	28 (82.4)	14 (93.3)	14 (73.7)	0.14
Disease duration, years	4.3 ± 3.6	1.1 ± 0.9	6.8 ± 2.9	0.001
BMI, Kg/m²	25.9 ± 6.7	27.4 ± 8.7	24.7 ± 4.3	0.13
Smoking habit, n (%)	12 (35.5)	4 (26.7)	8 (42.1)	0.35
Anti-CCP^pos, n (%)	28 (82.4)	12 (80.0)	16 (84.2)	0.79
RF-IgM^pos, n (%)	20 (58.8)	6 (40.0)	14 (73.7)	0.05
RF-IgA^pos, n (%)	16 (47.1)	3 (20.0)	13 (68.4)	0.01
ESR, mm/1^{^}hour	42.3 ± 23.7	38.7 ± 28.0	45.2 ± 19.3	0.27
CRP, mg/L	16.0 ± 15.6	14.2 ± 14.2	17.5 ± 13.3	0.44
DAS	3.9 ± 0.9	4.0 ± 0.1	3.9 ± 0.9	0.30
CDAI	30.0 ± 10.2	33.9 ± 10.2	27.5 ± 9.7	1.00
SDAI	31.3 ± 10.7	35.2 ± 10.6	28.8 ± 10.3	0.82
HAQ	1.2 ± 0.7	1.3 ± 0.8	1.2 ± 0.7	0.51
Erosive disease, n (%)	19 (55.9)	5 (33.3)	14 (73.7)	0.02
csDMARDs (ongoing), n (%)	34 (100.0)	15 (100.0)	19 (100.0)	-

Values are mean ± standard deviation unless otherwise indicated. RA rheumatoid arthritis, BMI body mass index, ESR erythrocyte sedimentation rate, CRP C-reactive protein, DAS Disease Activity Score, ACPA anti-citrullinated peptide antibodies, RF rheumatoid factor, CDAI Clinical Disease Activity Index, SDAI Simplified Disease Activity Index, csDMARDs conventional synthetic disease-modifying anti-rheumatic drugs, HAQ Health Assessment Questionnaire. *Mann–Whitney U test or chi-square test as appropriate between RA cohort 1 and RA cohort 2

ISSN: 1478-6362